CompletedNCT00635700
Ziprasidone or placebo for early psychosis symptoms
About this title
Read the official source — NCT00635700Medication studyAges 16–40United States + CanadaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 16 years to 40 years.
- Listed locations
- La Jolla and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMarch 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 51
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada
- Age range
- From 16 Years to 40 Years
- Official registry ID
- NCT00635700
- Official title
Show the full official title
Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
La Jolla, United States · Los Angeles, United States · San Francisco, United States
8 more locations
- New Haven, United States
- Atlanta, United States
- Boston, United States
- Worcester, United States
- Detroit, United States
- Glen Oaks, United States
- Chapel Hill, United States
- Calgary, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Did this study involve medication?
Yes. The study involved medication, including ziprasidone and placebo.
Who was this study for?
Listed age limits: 16 years to 40 years.
